PMEF
MDGL icon

Point72 Middle East FZE’s Madrigal Pharmaceuticals MDGL Stock Holding History

Point72 Middle East FZE’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,009
Closed -$244K – 1868
2023
Q1 		$244K Buy
+1,009
New +$275K 0.01% 887

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Point72 Middle East FZE's MDGL Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2023, closing a stake of 1,009 shares — an estimated $244K sold.

Point72 Middle East FZE first reported a position in MDGL in Q1 2023 and held it in 1 quarter. The position peaked at $244K in Q1 2023. 208 funds tracked by Wall St. Rank hold MDGL as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Madrigal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,009 Madrigal Pharmaceuticals shares in Q2 2023, an estimated $244K.
  • Point72 Middle East FZE first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Madrigal Pharmaceuticals position peaked at $244K in Q1 2023.
  • 208 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.